DETECT‐AD (Digital Evaluations and Technologies Enabling Clinical Translation for Alzheimer’s Disease): Baseline results of a simulated anti‐amyloid clinical trial using digital biomarkers
Digital biomarkers can be integrated into anti-amyloid designed trials. Stable baseline DB measures between Aβ "negative" and "positive" patients sets the stage for sensitively observing divergent DB trajectories over time.
Authors
- Kirsten M. Wright (ORCID: https://orcid.org/0000-0002-6913-7422)
- Zachary Beattie (ORCID: https://orcid.org/0000-0002-4844-7122)
- Sarah Gothard (ORCID: https://orcid.org/0009-0008-6799-2688)
- Nora Mattek (ORCID: https://orcid.org/0000-0003-2623-1969)
- Jennifer Marcoe (ORCID: https://orcid.org/0000-0001-7773-6225)
- Joel S. Steele (ORCID: https://orcid.org/0009-0008-4127-5664)
- Alex Speers (ORCID: https://orcid.org/0000-0001-5580-3298)
- Lisa C. Silbert (ORCID: https://orcid.org/0000-0002-4525-0068)
- Amanda B Mar
- Aimee Pierce
- Yanan Shang
- Daniel Schwartz
- Elise J Hanna
- Wan‐Tai Michael Au‐Yeung
- Chelsea A Thomas
- Jeffrey A Kaye
Institutions
- Oregon Health & Science University (US)
- University of North Dakota (US)
- Portland VA Medical Center (US)
- Alzheimer’s Disease Neuroimaging Initiative (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_106111
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00